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Fine-tuning of macrophage 
activation using synthetic  
rocaglate derivatives
Bidisha Bhattacharya1, Sujoy Chatterjee1, William G. Devine2, Lester Kobzik3, 
Aaron B. Beeler2, John A. Porco Jr2 & Igor Kramnik1
Drug-resistant bacteria represent a significant global threat. Given the dearth of new antibiotics, 
host-directed therapies (HDTs) are especially desirable. As IFN-gamma (IFNγ) plays a central role in 
host resistance to intracellular bacteria, including Mycobacterium tuberculosis, we searched for small 
molecules to augment the IFNγ response in macrophages. Using an interferon-inducible nuclear protein 
Ipr1 as a biomarker of macrophage activation, we performed a high-throughput screen and identified 
molecules that synergized with low concentration of IFNγ. Several active compounds belonged to the 
flavagline (rocaglate) family. In primary macrophages a subset of rocaglates 1) synergized with low 
concentrations of IFNγ in stimulating expression of a subset of IFN-inducible genes, including a key 
regulator of the IFNγ network, Irf1; 2) suppressed the expression of inducible nitric oxide synthase and 
type I IFN and 3) induced autophagy. These compounds may represent a basis for macrophage-directed 
therapies that fine-tune macrophage effector functions to combat intracellular pathogens and reduce 
inflammatory tissue damage. These therapies would be especially relevant to fighting drug-resistant 
pathogens, where improving host immunity may prove to be the ultimate resource.
Antibiotic-resistant bacteria pose a global threat, already producing profound medical and socio-economic 
impact in both developed and developing nations. Since pathogens acquire drug resistance faster than develop-
ment of new antibiotics1,2, alternative approaches to cure infections caused by antibiotic-resistant bacteria are 
urgently needed. Therefore, efforts to develop host-directed therapies (HDTs) focusing on disease pathogenesis, 
rather than eradicating pathogens with antibiotics, have been renewed3,4.
Broadly, HDTs could work either by 1) stimulating beneficial effector mechanisms of host immunity (resist-
ance) or by 2) reducing tissue damage inflicted either directly by a pathogen or by the immune response and 
inflammation. Several successful macrophage-based screens were focused on identifying compounds that 
increase control of intracellular bacteria in vitro with the idea to use those compounds to boost effector immunity 
in vivo3,5. Compounds that stimulate autophagy and promote the delivery of intracellular bacteria to lysosomes 
to be inactivated exemplify this approach6. The second group encompasses anti-inflammatory HDTs, such as 
corticosteroids and inflammatory cytokine inhibitors, many of which, however, suppress effector mechanisms of 
immunity. Such HDTs should be used only in combination with antibiotics and, therefore, are of limited utility 
in cases of infections caused by drug-resistant bacteria. An original approach has been pursued by Roca et al., 
who treated macrophages with high concentrations of TNFα , which induced maximal effector activity against 
mycobacteria, but also caused macrophage damage and death via a necroptotic pathway. By inhibiting specific 
mechanisms of TNFα -induced macrophage death in their model, the authors prevented the cytotoxic effect of 
high concentrations of TNFα , while preserving the resulting increase in microbicidal activity of macrophages7.
The IFNγ pathway represents another promising target for HDTs. It is essential for resistance to a broad range 
of intracellular pathogens, including various mycobacterial species, as convincingly demonstrated both in exper-
imental mouse models and clinical studies8–10. In mycobacterial infections, IFN-mediated pathways play dual 
roles. First, IFNγ primes macrophages for full activation and potentiates production of highly toxic NO and reac-
tive oxygen species (ROS) in response to activating stimuli, such as TNFα or bacterial ligands. It also has been 
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found to reduce inflammation and reduce tissue damage during tuberculosis independently of bacterial control11. 
During chronic infections, bioavailability of IFNγ may be reduced by co-infections (HIV or helminths), circulat-
ing IFNγ -neutralizing autoantibodies12–14 among other causes. Therefore, recombinant IFNγ and IFNγ -mimetics 
that activate macrophages by binding to IFNγ receptor were proposed to substitute for the natural ligand15,16. 
However, successful intracellular bacterial pathogens have evolved diverse mechanisms not only to suppress the 
IFNγ production by T cells, but also to down-regulate the responsiveness of macrophages to this cytokine17. 
Besides, sequestration of macrophages and bacteria within chronic lesions such as TB granulomas may also limit 
delivery of IFNγ . An alternative strategy would be to increase macrophage sensitivity to IFNγ . Hypothetically, 
small molecules that synergize with low doses of IFNγ may include compounds that mimic the well-documented, 
but poorly understood, anti-inflammatory activity of IFNγ in vivo.
Our previous studies indicate that the sst1/IPR1 pathway is one of the mechanisms of host resilience activated 
by IFNγ . Using a forward genetic analysis in a mouse TB model, we have characterized a genetic locus sst1 that 
specifically controls necrotization of TB granulomas, as well as inflammation and necrosis within inflammatory 
lesions caused by several taxonomically unrelated intracellular bacterial pathogens that reside in macrophages 
(Chlamydia pneumoniae, Francisella tularensis and Listeria monocytogenes)18–20. Using positional cloning, we have 
identified an interferon-inducible nuclear protein Ipr1/Sp110 within the sst1 locus and demonstrated that it medi-
ates the sst1 effect by regulating macrophage activation and death pathways18.
Subsequently we have determined that the Ipr1 protein levels in the nuclei of activated macrophages are con-
trolled by IFNγ in a dose-dependent manner. We exploited this relationship to develop a high-throughput screen 
for small molecules that enhance effect of IFNγ in macrophages. This screen identified the rocaglate family of 
compounds on the basis of their capacity to significantly increase levels of nuclear GFP-Ipr1 protein in synergy 
with IFNγ in a reporter macrophage cell line. We used alternative readouts in primary macrophages to confirm 
and mechanistically dissect the rocaglate synergy with IFNγ .
Results
Ipr1 is a nuclear protein regulated by type 1 and type 2 interferons via transcriptional and 
post-transcriptional mechanisms. For inducible expression of GFP-tagged Ipr1 fusion protein in the 
mouse macrophage cell line J774.A1, we used a doxycycline-inducible promoter and lentiviral delivery system 
as described elsewhere21. Clones that displayed no detectable basal GFP and high levels of inducible GFP-Ipr1 
expression, were identified using flow cytometry. One of those clones (J7-21) was used for subsequent analyses 
and assay development. The inducible GFP-Ipr1 expression was confirmed using Ipr1-specific rabbit polyclonal 
(Fig. 1a and S1) and mouse monoclonal antibodies developed in our laboratory (Fig. 1e,h).
Surprisingly, transcriptional activation of GFP-Ipr1 using doxycycline (Dox) alone was insufficient to induce 
accumulation of the fusion protein in macrophage nuclei or cytoplasm. Meanwhile, high levels of GFP-Ipr1 
and endogenous Ipr1 proteins were detected in the nuclei of macrophages co-treated with Dox (1 μg/mL) and 
100 U/mL of IFNγ (Fig. 1a,d). The identity of GFP-Ipr1 in the nuclei was also confirmed using co-staining with 
Ipr1-specific monoclonal antibody (Fig. 1e). As shown in Fig. 1b, the kinetics and levels of GFP-Ipr1 in the nuclei 
of IFNγ -activated macrophages paralleled those of the endogenous Ipr1 protein. Both GFP-Ipr1 and endogenous 
Ipr1 appeared in nucleoplasmic fractions within 6 hrs of macrophage activation with IFNγ and associated with 
chromatin by 12 hrs (Fig. 1c). To further study association of Ipr1 with chromatin we performed immunoprecip-
itation of nucleoplasmic and chromatin fractions using GFP-specific antibodies. We found that in the chromatin 
fraction GFP-Ipr1 associated with heterochromatin in a time-dependent manner (Supplementary Fig. S1).
In primary macrophages, Ipr1 mRNA transcripts were up-regulated at three hours after treatment with IFNγ , 
peaked at 12 hrs and decreased by 24 hrs, but remained significantly elevated as compared to non-activated mac-
rophages (Fig. 1f). The effect of IFNγ on Ipr1 mRNA expression was dose-dependent (Fig. 1g). The Ipr1 protein 
levels also increased in the nuclei, but not cytoplasm, of BMDMs within 24 hours of stimulation with type I 
(IFN-β ) or type II (IFNγ ) interferons (Fig. 1h, upper panel). Endogenous Ipr1 also associated with chromatin in 
IFNγ -activated primary macrophages (Fig. 1h, lower panel).
Taken together, these results demonstrate that Ipr1 is an interferon-inducible nuclear protein whose abun-
dance, distribution and stability are regulated by interferons at transcriptional and post-transcriptional levels. 
Moreover, post-transcriptional regulation of GFP-Ipr1 stability and nuclear localization in J7-21 cells by IFNγ 
mimics those of the endogenous Ipr1 protein. The association of both proteins with chromatin upon macrophage 
activation points towards a potential physiological role in chromatin dynamics and/or function induced by 
interferons.
The development of a cell-based assay for identifying compounds that synergize with IFNγ 
based on GFP-Ipr1 nuclear accumulation. To develop the screening protocol, we performed time course 
and dose-response analyses of GFP-Ipr1 expression using an automated cytometry system (Celigo) in a 96-well 
format. After treatment with IFNγ and Dox, J7-21 cells were fixed, stained with DAPI and analyzed using Celigo 
on GFP and DAPI channels. GFP fluorescence within nuclear areas delineated by DAPI staining was plotted 
against total the DAPI signal as presented in Fig. 2a. Gating on the upper left quadrant that contains diploid cells 
with elevated expression of GFP-Ipr1 in the nuclei was used to normalize the GFP signal against DNA content 
and provided more specific measure of GFP-Ipr1 induction as compared to total GFP signal. We used this gating 
strategy to determine thresholds for enumeration of GFP-positive nuclei in subsequent experiments and high 
throughoutput screening.
Time course analysis demonstrated that the macrophage response induced by maximal concentration of IFNγ 
(100 U/mL) in our assay peaked at 48 hrs (Fig. 2b). Meanwhile in the nuclear fraction of Dox-treated naive J7-21 
cells, we observed the appearance of discrete lower molecular weight bands, also recognized by the Ipr1-specific 
antibodies (Supplementary Fig. S2), indicating that the Ipr1 protein is cleaved in the nuclei. Next, we determined 
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the requirement of IFNγ and Dox for the GFP-Ipr1 protein nuclear accumulation. The experimental design is 
outlined schematically in Fig. 2c, upper panel: (Group 1) Dox + IFNγ was kept throughout the course of the 
experiment; (Group 2) IFNγ was removed after 24 hrs, fresh Dox was added and kept throughout; (Group 3) 
Dox was removed after 24 hrs and IFNγ kept throughout; (Group 4) both Dox and IFNγ were removed after 
24 hrs. GFP-Ipr1 gradually disappeared from the nuclei, if Dox was removed no matter whether IFNγ was present 
(Group 3), or absent (Group 4). Meanwhile, transient priming with IFNγ for the initial 24 hrs was sufficient to 
support the nuclear accumulation of GFP-Ipr1 protein for the next 24–48 hrs, if de novo synthesis of GFP-Ipr1 was 
maintained by Dox (Group 2) (Fig. 2c, lower panel). These results demonstrated constant turnover of GFP-Ipr1 
in macrophage nuclei and a lasting change conferred by transient IFNγ treatment, presumably at chromatin level 
that persisted for at least 24 hrs after removal of IFNγ . Next, we treated J7-21 cells with increasing concentrations 
of IFNγ for 24 hours, removed IFNγ and added Dox (Fig. 2d, upper panel). Nuclear GFP-Ipr1 accumulation was 
determined using Celigo cytometer at 24 hr intervals (Fig. 2d, lower panel). This experiment demonstrated that 
after transient stimulation with IFNγ , macrophages retained the ability to accumulate GFP-Ipr1 protein in their 
Figure 1. IFNγ regulates expression of Ipr1 at transcriptional and posttranscriptional levels in the nucleus 
of macrophages. (a) Expression of GFP-Ipr1 and endogenous Ipr1 in macrophage cell line J774A.1 clone J7-21. 
Nuclear extracts were prepared from J7-21 cells untreated (−) or treated with 1 μg/mL dox and/or 100 U/mL 
IFNγ for 24 hrs. GFP-Ipr1 and endogenous Ipr1 proteins were detected by immunoblotting; (b) Nuclear extracts 
from J7-21 cells treated with 1 μg/mL dox and/or 100 U/mL IFNγ for indicated times were prepared and 
GFP-Ipr1 expression was detected by immunoblotting. (c) Nuclei of J7-21 cells treated with 1 μg/mL dox and 
100 U/mL IFNγ for 24 hrs were fractionated into nucleoplasmic and chromatin fractions and endogenous Ipr1 
and GFP-Ipr1 was detected by immunoblotting. All immunoblots were carried out using Ipr1 specific rabbit 
polyclonal antibodies. (d) Immunofluorescence of J7-21 cells treated with 1 μg/mL dox alone and in presence of 
100 U/mL IFNγ for 24 hrs for GFP-Ipr1 detection (FITC channel). (e) J7-21 cells were treated with 1 μg/mL dox 
and 100 U/mL IFNγ for 24 hrs and stained with Ipr1-specific monoclonal antibody (red, central panel), eGFP-
Ipr1 is green (left panel) and merged image is yellow (right panel). (f) Real time RT-PCR analysis of the kinetics 
of Ipr1 mRNA expression in primary macrophages (C57BL/6 J BMDMs) after treatment with10 U/mL IFNγ 
for indicated times. (g) Dose dependent effect of IFNγ on Ipr1 mRNA expression in primary macrophages. B6 
BMDMs were treated with indicated doses of IFNγ for 18 hrs. Ipr1 mRNA expression was determined using 
real-time RT-PCR, normalized to expression of RPS17 mRNA and presented relative to expression in untreated 
cells (set as 1). All qPCR results represent data from two independent experiments. (h) Top panel - Ipr1 protein 
expression in primary macrophages. Immunoblot analysis of nuclear and cytoplasmic extracts of C57BL/6 
BMDM treated with 10 U/mL of IFNγ and 100 U/mL IFNβ for 24 hrs using Ipr1 specific polyclonal antibodies. 
Immunoblots represent data from at least two independent experiments. Lower panel - Immunofluorescence of 
B6 BMDMs stimulated with 10 U/mL IFNγ for 24 hrs showing nuclear localization of Ipr1. Cells were stained 
with anti-Ipr1 monoclonal antibody (red); nuclei are counterstained with DAPI (blue). All microscopic images 
represent data from at least two independent experiments.
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Figure 2. Development and validation of GFP-Ipr1 based screen for small molecules. (a) J7-21 cells were 
treated with 0.2 U and 10 U/mL IFNγ in presence of 1 μg/mL dox for 24 hrs and GFP-Ipr1 expression measured. 
The gating strategy (mentioned in text) was used to quantify GFP-Ipr1 expression. (b) J7-21 cells were treated 
with 1 μg/mL dox alone (0 U/mL IFNγ ) or in presence of 100 U/mL IFNγ for indicated times and fluorescence 
intensity of GFP-Ipr1 was measured. (c) J7-21 cells were primed with 1 μg/mL dox and 100 U/mL IFNγ for 
24 hrs and then subjected to the following treatments for additional 72 hrs: 1.dox and IFNγ kept throughout, 
2.dox kept and IFNγ removed, 3.dox removed and IFNγ kept, 4.dox and IFNγ removed. GFP-Ipr1 expression 
was measured using the celigo cytometer. (d) J7-21 cells were primed with 5, 25 and 100 U/mL IFNγ for 24 hrs 
and then removed. 1 μg/mL dox was added and expression of GFP-Ipr1 was measured after 24, 48 and 72 hrs.  
(e) J7-21 cells were treated with different doses of IFNγ for 24 hr. The next day dox(1 μg/mL) was added for 
24 hrs and % of cells expressing GFP-Ipr1 was calculated. A schematic representation of the experiment for 
C, D and E are shown. (f) J7-21 cells were treated with different doses of AM580 and PMA in presence of 
IFNγ (0.2 U/mL) and 1 μg/mL dox and fluorescent intensity of GFP-Ipr1 expression was measured. Cells 
expressing GFP-Ipr1 was calculated as % expression with respect to 10 U/mL IFNγ . All graphs are representative 
of at least two independent experiments. (g) Immunoblot analysis of whole-cell extracts of J7-21 cells treated 
with 8 μM PMA and 10 μM AM580 in presence and absence of 0.2 U/mL IFNγ and 1 μg/mL dox for 24 hrs. 
Blots were probed with Ipr1 polyclonal antibodies. Blots are representative of two independent experiments. 
Fold induction of GFP-Ipr1 was calculated relative to expression in untreated cells (set as 1) by densitometric 
analysis after normalizing it to loading control β -actin. (h) Microscopy of BMDM from C57BL/6 mice cultured 
with 2 μM PMA and 3.3 μM AM580 in presence of 0.2 U/mL IFNγ for 24 hrs and stained with Ipr1 monoclonal 
antibody(red). Images represent data from two independent experiments performed in duplicates.
www.nature.com/scientificreports/
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nuclei in an IFNγ - dose and time-dependent manner. This observation suggested that the nuclear accumulation 
of GFP-Ipr1 can be used as a quantitative readout for the IFNγ -primed state of macrophages.
A series of optimization steps for the high-throughput format were performed to minimize handling errors 
and to attain high well-to-well and plate-to-plate consistency. The finalized screening protocol is presented in 
Fig. 2e (upper panel): J7-21 cells are primed with IFNγ for 24 hrs; after that Dox (1 μg/mL) is added without wash-
ing; and nuclear GFP-Ipr1 protein expression is measured using automated cell cytometer (Celigo) after 24 hrs of 
Dox addition. In this protocol, stimulation with IFNγ alone produced high sensitivity and linearity in the range of 
0.5–10 U/mL of IFNγ (Fig. 2e, lower panel). To screen for compounds that synergize with low doses of IFNγ , we 
selected 0.2 U/mL of IFNγ - the concentration at which the initial inflexion of GFP-Ipr1 expression was evident 
in the IFNγ concentration-response curve (Fig. 2e). The J7-21 cells were plated for 24 hrs before priming. First, 
IFNγ was added to a final concentration of 0.2 U/mL, immediately followed by adding the library of compounds. 
The cells were incubated for 24 hrs and Dox (1 μg/mL) was added for additional 24 hrs to induce GFP-Ipr1 expres-
sion. Thus, the cells were treated with 0.2 U/mL of IFNγ and small molecules for a total of 48 hrs before fixation. 
After that the nuclei were stained with DAPI and images were acquired using Celigo cytometer. Each compound 
was tested in triplicate and the wells treated with IFNγ alone at 0.2 U/mL were used to set a threshold and wells 
treated with 10 U/mL IFNγ served as positive controls. For each compound we calculated percentages of nuclear 
GFP-Ipr1 positive cells above the threshold (0.2 U/mL of IFNγ alone).
A pilot study and orthogonal validation. We performed a pilot study using two small molecule librar-
ies: the ICCB library and the LOPAC library. The ICCB library is a collection of 472 diverse biologically active 
compounds with defined biological activity developed at the Harvard Institute of Chemistry and Cell Biology. 
The LOPAC (Library of Pharmacologically Active Compounds, Sigma) consists of 1280 compounds with known 
bioactivity. We identified 24 compounds that increased the expression of GFP-Ipr1 in the presence of 0.2 U/mL 
IFNγ at least four-fold above the threshold in two independent experiments. Based on their biological properties, 
we then subdivided these active compounds into two major functional categories: i) compounds that stabilized 
the GFP-Ipr1 protein by preventing its degradation by proteases (e.g. leupeptin and the pan-caspase inhibitor 
z-VAD) and ii) compounds known to increase macrophage activation directly (several retinoic acid receptor 
agonists (RAR) and a known protein kinase C activator phorbol myristate acetate (PMA).
We then selected two compounds from the second group; the RAR agonist AM580 and PMA for further assay 
validation. First, we performed dose-response analyses for these two compounds using the same assay described 
above (Fig. 2f). Next, we performed orthogonal validation of our assay using Western blot with Ipr1-specific 
polyclonal rabbit antibodies, which recognized both GFP-Ipr1 and endogenous Ipr1. As shown in Fig. 2g 10 U/
mL IFNγ induced the highest expression of both GFP-Ipr1 and endogenous Ipr1 proteins, while at 0.2 U/mL 
of IFNγ , levels of GFP-Ipr1 and the endogenous Ipr1 proteins were below detection levels. Neither PMA, nor 
AM580 alone induced Ipr1 expression, as well. However, in J7-21 cells primed with 0.2 U/mL, both PMA and 
AM580 induced GFP-Ipr1 and endogenous Ipr1 proteins. Next, we tested the ability of PMA and AM580 to 
synergize with 0.2 U/mL of IFNγ using mouse primary bone marrow-derived macrophages (BMDMs). The Ipr1 
protein was detected by immunofluorescence using Ipr1-specific monoclonal antibodies (Fig. 2h). While 0.2 U/
mL IFNγ alone did not induce nuclear Ipr1 accumulation, there was a significant increase in nuclear Ipr1 in 
BMDMs primed with 0.2 U/mL of IFNγ and treated with PMA or AM580. Again, priming with 0.2 U/mL of 
IFNγ was necessary for Ipr1 induction by either compound. Therefore using orthogonal assays we confirmed 
synergy between either AM580 or PMA with low dose IFNγ for induction of GFP-Ipr1 and endogenous Ipr1 
(both in a macrophage cell line as well as in primary macrophages). These data also pointed towards a plausi-
ble mechanism of the Ipr1 posttranscriptional regulation by phosphorylation and proteolytic cleavage. Indeed, 
Ipr1 protein sequence analysis predicted multiple phosphorylation and protease cleavage sites (Supplementary 
Fig. S2). We observed stabilization of GFP-Ipr1 in presence of a pan-caspase/cysteine protease inhibitor z-VAD 
(Supplementary Fig. S2), while in non-activated J7-21 cells GFP-Ipr1 underwent processing into fragments of 
lower molecular weight (Supplementary Fig. S2). blocking proteases alone with zVAD was insufficient to induce 
high levels of GFP-Ipr1 and endogenous Ipr1 proteins ( Supplementary Fig. S2). We hypothesize that phospho-
rylation of Ipr1 (induced in our screen by PMA) may mask its protease cleavage sites by causing conformational 
change and activation-induced protein complex formation (as shown previously)21, enabling GFP-Ipr1 translo-
cation to the nucleus, where it dynamically associates with target chromatin via its SAND domain and nuclear 
matrix via its Sp100 domain. Thus, the accumulation of nuclear chromatin-associated GFP-Ipr1 is likely to be 
a result of complex signaling and chromatin re-organization processes during macrophage activation. Taken 
together, these data provided both mechanistic insights and initial validation of our screening strategy.
Identification of novel rocaglates that work in synergy with IFNγ. To identify novel 
IFNγ -synergistic compounds, we screened a chemical library from the Boston University Center for Molecular 
Discovery (BU-CMD, www.bu.edu/cmd) which is freely available to biological collaborators. The library con-
sisted of 3840 compounds and is comprised of novel chemotypes rich in structural diversity. Testing the BU-CMD 
library led to the identification of 30 initial hits; ten of the hits were subsequently confirmed after re-testing 
in triplicates using quality-controlled compounds from frozen stocks. These candidate compounds (CCs) were 
subjected to in-depth analyses to exclude assay artifacts and to assess IFNγ -dependence of their activity. First, 
we tested the candidate compounds in J774 cells that do not express GFP-Ipr1, resulting in exclusion of two 
DNA intercalating fluorophores with non-specific nuclear fluorescence. Next we tested CCs in J7-21 cells in the 
presence of IFNγ but in the absence of doxycycline to exclude false positive compounds that would be able to 
substitute for Dox - none were found. Ultimately, three BU-CMD compounds were selected based on their activ-
ity and specificity. All of the top compounds [CMLD005557 (C5557), CMLD008808 (C8808), and CMLD009433 
(C9433)] were structurally related derivatives of the natural product rocaglamide A (rocaglates) (see below). 
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Compounds were subjected to quality control (QC) analysis and their activity was confirmed using our ini-
tial screening assay. We measured dose-response effects on GFP-Ipr1 expression using the J7-21 clone-based 
assay of all three CCs in a concentration range 0.03–3.3 μM. The specific activity of C9433 was the highest and 
dose-dependent with an IC50 of 160 nM (Fig. 3a). Toxicity of C5557 and C8808 was higher in comparison to 
C9433 in J7-21 cells (not shown), but in primary macrophages all three CCs exhibited low toxicity (Fig. 3b). 
Because rocaglates are known to inhibit protein translation, we compared the effects of C9433, C8808 and C5557 
effects on protein biosynthesis using a reporter cell line 293TR-Fluc expressing firefly luciferase under the control 
of a constitutive promoter22. Within the range of concentrations used in our assays, C9433 and C5557 displayed 
similar translation inhibition activities (IC50 values 53 nM and 45 nM respectively) while C8808 was less potent 
Figure 3. CMLD candidate compound identification and validation. (a) Dose response in J774-21 GFP-Ipr1 
reporter cell line. J7-21 cells were treated with different doses of C9433 (0.010, 0.033, 0.1, 0.33, 1, 3.3 μM) in 
the presence of 0.2 U/mL IFNγ for 24 hrs, followed by addition of 1 μg/mL dox for 24 hrs. GFP-Ipr1 expression 
was measured using automated cytometry. Results are representative of at least two independent experiments 
performed in triplicates. (b) Toxicity of compounds in primary BMDM. BMDM were treated with compounds 
C9433, C5557 and C8808 at concentrations shown for 24 hrs and % of PI positive cells were calculated. Data 
is represented as % of survival of two independent experiments performed in duplicates. (c) Dose-dependent 
translation inhibition by rocaglates. 293TR-FLuc cells were treated with rocaglates C9433, C5557 and C8808 
(0.033, 0.1, 0.33, 1, 3.3 μM) and luciferase activity was measured after 18 hrs. Two independent experiments 
were performed in triplicates. (d) Comparative effect of 1 μM rocaglates C9433, C5557 and C8808 on gene 
expression. BMDM were treated with 1 μM compound for 24 hr and the mRNA expression of Irf1, Igtp and 
Irgm1, Irf5, Gadd45b and Ptgs2 was measured by real-time PCR. (e) Effect of C9433 on IFNγ -inducible gene 
expression. BMDM was treated with different doses of C9433 (0.33, 1, 3.3 μM) in presence and absence of 0.2U 
IFNγ for 24 hrs and mRNA expression of Irf7, Irf1 and Ido1 was measured by real-time PCR. Cells treated 
with 20 U/mL IFNγ served as a positive control of gene expression. PCR data are representative of at least two 
independent experiments.
www.nature.com/scientificreports/
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(IC50 value 100 nM), suggesting that specific activities of the CCs in our assay did not strictly parallel their trans-
lational inhibition activities (Fig. 3c).
C9433 modulates IFNγ-driven gene expression in primary macrophages. To further character-
ize the effects of the rocaglates, we used primary bone marrow-derived macrophages (BMDMs) isolated from 
C57BL/6 J mice. We compared effects of C9433, C8808 and C5557 at 1 μM (non-toxic concentration, Fig. 3b) 
on expression of several interferon-inducible genes using qRT-PCR. The combination of C9433 with 0.2 U/mL 
of IFNγ produced much stronger synergistic effect on Irf1, Igtp and Irgm1 mRNA expression, as compared to 
C5557 and C8808 (Fig. 3d, upper panels). Next, we compared direct effects of those compounds on expression 
of genes known to be involved in macrophage differentiation and inflammatory responses. We found that Irf5, 
Ptgs2 and Gadd45b (MyD118) were induced selectively by C9433, but not with C5557 and C8808 (Fig. 3d, lower 
panels). These genes are known to participate in control of macrophage differentiation (Irf523 and Gadd45b) and 
inflammation (Ptgs2)24.
To further evaluate the compound C9433, a new batch was synthesized and characterized at the BU-CMD 
(as described in Supplementary Fig. S3) to assure reproducibility. Next, we compared C9433 and 0.2 U/mL 
co-stimulation with that of 20 U/mL of IFNγ , the plateau concentration of IFNγ causing changes in gene expres-
sion in our assay. We tested expression levels of several IFNγ -inducible genes representing different physiological 
pathways controlled by IFNγ : Irf1, Irf7, Ido1 (Fig. 3e). Remarkably, the combination of C9433 with 0.2 U/mL 
of IFNγ produced a very strong synergistic effect on Irf1 mRNA expression, exceeding levels of the Irf1 mRNA 
induced by 20 U/mL of IFNγ (Fig. 3e). In contrast, the Irf7 and Ido1 mRNA levels induced by the co-stimulation 
were well below those induced by 20 U/mL of IFNγ . Irf1 is a transcription factor directly induced after IFNγ 
binds to its specific receptor, and plays a central role in orchestrating macrophage responses to this cytokine25. It 
is essential for host resistance to TB26,27. Meanwhile, the effects of the IFN-I pathway, which are mediated by Irf7, 
have been linked to immunosuppression and immunopathology in vivo28. Therefore, shifting the Irf1/Irf7 bal-
ance towards Irf1 using C9433 may boost IFNγ -mediated mechanisms of macrophage resistance and also reduce 
immunopathology in vivo.
Microarray analysis. To characterize effects of C9433 on macrophage priming with low dose of IFNγ on 
a global scale, we performed gene expression profiling using Affymetrix Mouse GeneChip 430.2 ST arrays. 
Comparing BMDMs co-stimulated with C9433 (1 μM) and IFNγ (0.2 U/mL) for 24 hrs to those stimulated 
with 0.2 U/mL IFNγ alone, we found that 3063 genes were differentially expressed (p < 0.001). Pathway anal-
ysis using the Ingenuity package suggested the up-regulation of the Nrf2-mediated oxidative stress response 
and the Integrin-linked kinase (ILK) pathways. The top down-regulated genes were involved in cholesterol 
biosynthesis pathways, where the expression of genes encoding two key enzymes in cholesterol biosynthesis 
DHCR7 and DHCR24 were down-regulated 7.5- and 10-fold respectively. The TGFβ pathway was also found 
to be down-regulated, consistent with macrophage activation. Among activated pathways relevant to mac-
rophage functions, were those linked to CDKN1 (p21Waf, z-score = 2.86), Vitamin D3 (z-score = 4.5) and 
Irgm1(z-score = 3.45). Raw microarray data have been deposited in the Gene Expression Omnibus (GEO) as 
Series GSE72435.
We further explored the C9433 expression signature by using the LINCS1000 tool29. After entry of the top 
500 up- and down-regulated genes, the program recognized the genes listed in Supplementary Table S1 and per-
formed an expanded version of connectivity map analysis. The results show that the C9433 expression signature 
is similar to those caused by perturbations that inhibit proteosome (MG132, bortezomib) or protein translation 
(puromycin, emetine) in the panel of cell lines used in the LINCS1000 platform. Similarly, a comparison of the 
C9433 expression signature to signatures caused by shRNAs was performed and then sorted to identify the top 
50 by percentile rank. This list of targets is also enriched for genes linked to proteasome or protein synthesis 
functions (Supplementary Table S1). As proteosome inhibition induces proteotoxic stress leading to translation 
repression, this analysis confirms a known property of other rocaglate compounds - inhibition of translation. 
Indeed, using a reporter cell line we found that at concentrations used in our assays, C9433 significantly reduced 
translation (Fig. 3c). In addition, comparison of the C9433 effect on gene expression to signatures caused by 
over-expression of genes identified 11 genes in the top 10th percentile (i.e. their overexpression caused a similar 
gene expression profile). Among these genes (BCL10, IFNG, IFNB1, MAGEB6, CDKN1A, TRAF2, CDKN2C, 
CD40, UGCG, GADD45B, HNF4A, LTBR), IFNG and CDKN1A were also identified in the pathway analysis dis-
cussed above. Moreover, we found that C9433 directly induced Gadd45b expression (Fig. 3d), which is consistent 
with the up-regulation of GADD45B-dependent gene expression signature.
In GSEA analysis, the highest positive normalized enrichment score (1.81) was for genes that contained a 
NF-κ B element in their promoters, suggesting that C9433 in combination with IFNγ enhanced NF-κ B activity. 
The expression of NF-κ B -inducing kinase (NIK, Map3K14) and TNFα were up-regulated 5-fold suggesting 
a potential mechanism for NF-κ B activation. In addition, up-regulation of a number of stress response genes 
(ATF4, ATF6, Ddit3, Trib3, Gadd45b, Gadd45g, Hspa1a, and Osgin1) suggested that activation of stress responses 
might contribute to NF-κ B activation by C9433 as well. NF-κ B activation may explain superinduction of the Irf1 
gene, since it contains a combinatorial NF-κ B/GAS element in its promoter30. Several other interferon-inducible 
genes were up-regulated in C9433 plus IFNγ co-stimulated cells (irg1, ifi205, ifit1, ifrd1, igtp). Notably an 
interferon-inducible negative regulator of IFN-I pathway Usp18 was up-regulated 7.8-fold. We confirmed the 
C9433-mediated suppression of the IFN-I pathway in an independent assay, where macrophages were stimulated 
with TNFα (10 ng/mL), a treatment known to induce moderate IFN-I pathway activation31. We observed potent 
suppression of IFNβ , and its downstream targets IP-10 and IL-10 by C9433 (Fig. 4h). Perhaps, the direct suppres-
sive effect of C9433 on the IFN-I pathway may partially account for the sensitization of macrophages to IFNγ ,as 
the two pathways are known to antagonize each other32.
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Figure 4. C9433 induces autophagy in primary macrophages and promotes bacterial clearance. (a) BMDM 
were treated with different doses of C9433 for 16 hrs and probed with LC3B mAb. A mix of chloroquine(10 μM) 
and rapamycin(500 nM) was used as a positive control (C). (b) BMDM was treated with compound for 16 hrs 
and autophagy induction was determined using Cyto-ID Autophagy Detection kit. (c) BMDM were treated 
with 1 μM compound for indicated time and probed with LC3B mAb. (d) BMDM were treated with 1 μM 
compound for 6 hrs. Bafilomycin(50 nM) and chloroquine(30 μM) were added to the cells 2 hrs before harvesting 
and probed with LC3B antibody. All blots represent data from two independent experiments. (e) iBMM cells 
were treated with 1 μM compound for 6 hrs and autophagic puncta was detected using confocal microscopy. (f) 
BMDM were treated with 15 ng/mL TNFα and 10 U/mL IFNγ for 24 hrs in the presence and absence of C9433 
and NO production was determined. (g) iNOS expression was determined in the above samples using specific 
anti-iNOS antibody using celigo cytometer. Two independent experiments performed in triplicates. (h) BMDM 
were treated with 10 ng/mL TNFα in the presence of C9433 for 24 hrs. mRNA expression of IFNβ , IP10 and IL10 
were measured by q-PCR. Data is represented as % of gene expression relative to 10 ng/ml TNFα treated cells 
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We also observed a dramatic upregulation of the prostaglandin E biosynthetic pathway, as the expression of 
prostaglandin-endoperoxide synthase 2 (Ptgs2, validated using RT-PCR, Fig. 3d) and prostaglandin E synthase 
(Ptges) containing NF-κ B elements in their promoters, increased 16.3 and 3.7-fold respectively, while 15-hydroxy 
prostaglandin dehydrogenase, which degrades PgE2, was inhibited 34-fold. This coordinated change should lead 
to increased production of PgE2, which has been recently shown to benefit the host by downregulating the IFN-I 
pathway24 and improved membrane repair in macrophages infected with M.tb11.
Taken together, our microarray profiling results demonstrated significant reprogramming of macrophage tran-
scriptome by C9433 in combination with 0.2 U/ml of IFNγ that did not simply mimic activation with higher dose 
of IFNγ , but induced a biased response characterized by relative up-regulation of stress- and NF-κ B-responsive 
genes and suppression of IFN-I pathways.
C9433 induces autophagy and modulates macrophage effector functions. IFNγ is known to 
induce two major effector functions relevant for control of intracellular bacteria by macrophages: production of 
nitric oxide (NO) via activation of inducible NO synthase (iNOS) and induction of phagosome maturation and 
lysosome fusion via induction of autophagy.
As a general mechanism of cell survival under stress, macrophage autophagy has been also implicated in kill-
ing intracellular bacteria via stimulating trafficking of phagocytic vacuoles and promoting phagosome - lysosome 
fusion33–36. We noted that several interferon-inducible genes up-regulated by C9433 are also regulators of auto-
phagy (Irgm1 in Fig. 3d, Atg7). Therefore, we tested whether C9433 induced autophagy in BMDMs.
During autophagy LC3B-I (Atg8) is converted to LC3B-II through lipidation and inserts into the mem-
brane of autophagosomes. Then, autophagosomes fuse with lysosomes where LC3B-II is degraded by lysoso-
mal hydrolases. The relative increase of LC3B-II and accumulation of LC3-II positive autophagosomes signifies 
active autophagic flux. Using Western blot analysis with LC3B (Atg8)-specific antibodies, we observed that C9433 
(0.5–2 μM) induced the LC3B-I to LC3B-II conversion in a dose-dependent manner (Fig. 4a). To further ver-
ify the induction of autophagy, we used a cationic amphiphilic tracer (CAT) that selectively labels autophagic 
vacuoles (CYTO-ID Autophagy Detection Kit, Enzo Life Sciences). Indeed, treatment of BMDMs with C9433 
resulted in accumulation of the CAT-positive vacuoles (Fig. 4b). In a time-course experiment, a maximal LC3-II/
LC3-I ratio was observed after 6 hrs of C9433 treatment, which was followed by a decline of total LC3B (Fig. 4c). 
We demonstrated that LC3B depletion at 12 hrs reflected increased autophagic flux by using inhibitors of lysoso-
mal acidification and protein degradation, chloroquine and bafilomycin A1. Both inhibitors delayed lysosomal 
degradation of LC3B-II, but not LC3B-I, thus confirming the increase in LC3B-I to LC3B-II transition (Fig. 4d).
We further confirmed autophagy induction by C9433 using an immortalized macrophage cell line, which 
constitutively expressed eGFP-LC3 fusion protein. As shown in Fig. 4e, eGFP-LC3 fluorescence was largely dif-
fuse in untreated cells with few puncta denoting basal autophagosome formation. Within six hours of exposure 
to C9433, both eGFP-LC3 puncta-positive cells and the number of puncta per cell significantly increased demon-
strating autophagy activation. When autophagosomes fuse with lysosomes and eGFP-LC3II is degraded by lyso-
somal hydrolases, the LC3-II moiety is degraded faster than the more stable eGFP moiety, resulting in a transient 
accumulation of eGFP, which serves as an additional confirmation of phagocytic flux. Indeed, we observed a 
time-dependent accumulation of eGFP by C9433 treatment of the macrophage cell line using Western blot with 
GFP-specific antibodies (not shown).
Although IFNγ is a weak inducer of iNOS pathway, pretreatment with IFNγ potently primes macrophages 
for activation of iNOS expression and NO production by TNFα or bacterial ligands37. To test whether C9433 can 
synergize with low doses of IFNγ in priming macrophages for subsequent iNOS activation, we assessed its effect 
on iNOS expression following priming with IFNγ and stimulation with TNFα . At sub-threshold concentrations, 
isolated effects of each cytokine on NO production and iNOS mRNA and protein expression were minimal, but 
co-stimulation with IFNγ and TNFα produced strong synergistic effect on the induction of both iNOS mRNA 
and protein expression. Unexpectedly, we observed a potent suppressive effect of C9433 on NO production and 
iNOS expression in BMDM co-stimulated with TNFα and IFNγ . Even when we increased the IFNγ concentra-
tion to a standard stimulatory level (10 U/mL), C9433 potently inhibited the IFNγ priming effect on NO pro-
duction (Fig. 4f). We confirmed this suppressor effect by immunostaining of iNOS protein using automated 
cytometry (Fig. 4g) and microscopy (Supplementary Fig. S4).
Since C9433 suppressed NO production, one of the key macrophage effector mechanisms, we tested whether 
C9433 also compromised bacterial control after macrophage infection with intracellular bacteria Francisella tula-
rensis Live Vaccine Strain (F. t. LVS) in vitro. Priming BMDM with IFNγ effectively increases the control of F. t. 
LVS by human and mouse macrophages in a dose-dependent manner38,39. At 0.5 U/mL the effect of IFNγ on F. t. 
LVS replication in our model was minimal. Therefore, we treated BMDMs with IFNγ (0.5 U/mL), C9433, or a 
combination of both. After 18 hrs of priming, macrophages were infected at a multiplicity of infection (MOI) of 
from two independent experiments. (i) BMDMs were either untreated or pretreated with 2 μM C9433, 0.5 U/mL 
of IFNγ alone or in presence of compound for 16 hrs and then infected with F.t. LVS at MOI 1 for 24 hrs. 
Bacteria were detected using anti-F.t. LVS antibodies(red), nuclei counterstained with DAPI(blue).  
(j) 100 cells were counted per condition to detect intracellular bacteria and the % of infected cells were 
calculated. Microscope images represent data from at least two independent experiments. (k) F.t. LVS infected 
BMDM in presence and absence of compound were probed with anti-LC3B mAb. (l) BMDM were pretreated 
with C9433 for 16 hrs in the presence or absence of IFNγ and then infected with F.t. LVS at MOI 10. After 
7 hrs% of PI- positive cells were enumerated using celigo cytometer. Two independent experiments were 
performed in triplicates.
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1 or 10 bacteria per macrophage. Pretreatment of macrophages with C9433 either alone or in combination with 
0.5 U/mL of IFNγ did not increase but actually slightly decreased the number of intracellular bacteria per mac-
rophage and the number of infected cells at 24 hrs post infection (Fig. 4i, j). These results suggest that although 
C9433 suppresses NO pathway, it does not compromise the overall bacterial control by macrophages. It remains 
to be determined whether treatment with rocaglates helped control the bacteria in NO-independent manner via 
autophagy induction. Indeed, autophagy induced by F. tularensis in infected cells was shown to support bacterial 
replication by providing energy source to the bacteria40. However, we pretreated macrophages with C9433 prior 
to the infection, which induced autophagic flux earlier and more potently as compared to the infection alone 
(Fig. 4k). In these settings autophagy may stimulate host cell protective mechanisms, as well.
Infection with intracellular bacteria also causes membrane damage and temporal permeabilization of mac-
rophage membranes within hours41. Membrane damage is repaired in autophagy- and PgE2-dependent manner. 
Since C9433 stimulates both pathways, we wondered whether it might also prevent or reduce the membrane dam-
age induced by the F. t. LVS infection. We observed that F. t. LVS infection induced membrane permeabilization 
(PI positive cells) of IFNγ -primed macrophages within 7 hrs of infection (Fig. 4l). However, macrophages primed 
with IFNγ in the presence of C9433 had a significantly smaller fraction of PI-positive cells, suggesting that pre-
treatment with C9433 either reduced the membrane damage or enhanced the membrane repair.
A subset of rocaglates mimics the effects of C9433. We screened an additional library of 69 rocaglate 
derivatives from the BU-CMD collection and identified 5 novel compounds, whose activity in primary mac-
rophages was similar to C9433: at 1 μM they synergized with 0.2 U/mL of IFNγ as demonstrated by Irf1 and 
Irgm2 mRNA induction (Fig. 5a), and directly induced Irf5 and Ptgs2 mRNA expression (Fig. 5a). Next we 
ranked their synergistic activity at a lower concentration (0.3 μM): C8809 (#2) was the most active, while 10361 
(#6) was the least active (Fig. 5b and Supplementary Fig. S5). However, the translation inhibition effect of C9433, 
C8809, and C10361 (rocaglaol, a derivative of rocaglamide A) at 0.3 μM was similar (Fig. 5c). Thus, the effect of 
rocaglates on gene expression did not completely parallel their inhibitory activity on protein translation.
Since C8809 was the most active among the newly identified rocaglates, we compared its dose-dependent 
effects to that of C9433 on translation inhibition and Irf1 gene expression. While C9433 was a more potent 
translation inhibitor compared to C8809 with EC50 values of 53 nM and 140 nM, respectively (Fig. 5e), both com-
pounds had similar EC50 values in the Irf1 gene expression assay − 240 nM and 320 nM, respectively (Fig. 5d). 
Importantly, both compounds also induced IRF1 protein expression strictly in cooperation with 0.2 U/mL of 
IFNγ to levels similar to those induced by IFNγ alone at 20 U/mL(Fig. 5f).
Similar autophagy-inducing activities of C9433 and C8809 were demonstrated using Western blot analysis, 
which showed a dose-dependent increase in the expression of LC3BII protein (Fig. 5g), and confirmed using an 
immortalized macrophage cell line expressing eGFP-LC3 fusion protein (data not shown). Finally, C8809 sup-
pressed both NO production and iNOS expression in primary macrophages co-stimulated with TNFα and IFNγ 
in a dose-dependent manner (Fig. 5h and Supplementary Fig. S4), as well as the type I IFN pathway activation by 
TNFα (Fig. 5i). Thus, functional effects of C8809 and C9433 in macrophages substantially overlapped.
Translation inhibition by rocaglates is necessary for gene expression induction in primary mac-
rophages. All rocaglates identified in our primary screen (C9433, C8808, C5557 and C8809, Fig. 6) inhibited 
protein translation (Figs 3c and 5c), suppressed NO production and induced autophagy (the C8808 and C5557 
data are presented in Supplementary Fig. S6). We concluded that the autophagy induction and NO pathway inhi-
bition by rocaglates are mechanistically linked to their well-established translation inhibition activity. In this sce-
nario, the translational inhibition may directly lead to autophagy, which, in turn, would inhibit NO production, 
as described in the literature. However, these data also demonstrated that translation inhibition was not sufficient 
to account for the unique property of some rocaglates (most notably C9433 and C8809) to synergize with IFNγ 
in macrophage activation, as determined using gene expression analyses.
In order to determine whether translation inhibition was necessary, we tested silvestrol and rohitinib (RHT), 
two well-studied rocaglates possessing both potent translation inhibition and cytotoxic activities. Both are known 
to suppress the cap-dependent translation initiation complex eIF4F by binding to and inhibiting an RNA helicase 
(eIF4A)22,42,43. Both RHT and silvestrol showed significant toxicity at the highest two doses (1 and 3.3 μM) in pri-
mary macrophages (Fig. 7b) and potent translation inhibition (EC50 for silvestrol is 40 nM, for RHT it is 10 nM, 
Fig. 7e). Notably silvestrol was more toxic to primary macrophages, but was found to be less active in comparison 
to RHT. At 0.33 μM, the highest concentration that was not cytotoxic for primary macrophages within 24 hrs, 
both compounds synergized with IFNγ to induce Irf1 mRNA expression (Fig. 7a).
Next we compared activities of RHT and its isomers which are inactive as translation inhibitors (Fig. 7e) 
exo-RHT (exo-stereoisomer, CMLD10401) and ent-RHT (inactive enantiomer, CMLD10531)43,44(see 
Supplementary Fig. S7 for chemical structures). Neither exo-RHT nor ent-RHT stimulated Irf1 expression 
(Fig. 7a), inhibited NO production (Fig. 7c), nor induced autophagy (Fig. 7d). These data demonstrate that 
all of the above rocaglate activities, including synergy with IFNγ in gene expression, are linked to their abil-
ity to inhibit translation initiation. However, the known translation elongation inhibitor cycloheximide (EC50 
is 300 nM, Fig. 7f) completely failed to stimulate Irf1, Irf5 and Ptgs2 gene expression in macrophages (Fig. 7h). 
Note, the cycloheximide and RHT toxicities in our model were similar (Fig.7b,g). Rapamycin is a suppres-
sor of cap-dependent translation known to induce autophagy via inhibition of the mTOR pathway, in an 
eIF4A-independent manner. It also failed to stimulate the macrophage gene expression even at concentrations 
up to 3.3 μM (Fig. 7i), which still were not toxic for primary macrophages (Fig. 7g). Taken together, these data 
demonstrate that stimulation of gene expression in synergy with IFNγ by rocaglates is tightly associated with 
their activity to inhibit protein translation.
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Discussion
An unexpected outcome of these studies was the discovery of a unique property of a subset of rocaglates to syner-
gize with IFNγ in macrophage activation in addition to a more broadly distributed abilities of rocaglates to block 
protein translation and to induce stress response and autophagy in an IFNγ -independent manner.
Rocaglates and rocaglamide derivatives are cyclopenta-[b]benzofurans with unusual carbon skeletons found 
in the plant genus Aglaia which is indigenous to Southeast Asia. These compounds have been used in tradi-
tional Chinese medicine. Antileukemic and/or cytotoxic activity of certain rocaglamide derivatives has been 
reported34,45. Silvestrol (isolated from Aglaia foveolata) is a potent inhibitor of protein synthesis and has cytotoxic 
activity similar to many FDA-approved anticancer agents. More potent synthetic rocaglates are being developed 
Figure 5. Comparative activity and characterization of new rocaglates. (a) BMDM were treated with 1 μM 
compound (1-C9433, 2-C8809, 3-C10021, 4-C7564, 5-C7565, and 6-C10361) alone and in presence of 0.2 U/mL 
IFNγ for 24 hr. mRNA expression of Irf1, Irgm2, Irf5 and Ptgs2 was measured by qPCR. Data is presented 
relative to expression in untreated cells (set as 1). (b) BMDM were treated with 0.33 μM compounds (mentioned 
above) in presence and/or absence of 0.2 U/mL IFNγ for 24 hr. mRNA expression of Irf1, Irf5 and Ptgs2 was 
measured by qPCR. Data is presented relative to expression in 0.2U IFNγ treated cells for Irf1 and untreated for 
Irf5 and Ptgs2 (set as 1). (c) 293TR-FLuc cells were treated with 0.33 μM compounds (mentioned above) and 
luciferase activity was measured after 18 hrs. Data represents values from two independent experiments.  
(d) BMDM were treated with different doses of C9433 and C8809 in presence of 0.2 U/mL IFNγ for 24 hrs. 
mRNA expression of Irf1 was measured by qPCR. Data is presented relative to expression in 0.2U IFNγ treated 
cells (set as 1). (e) 293 T-FLuc cells were treated with different doses of C9433 and C8809 and the luciferase 
activity was measured after 18 hrs in triplicates. (f) BMDM were treated with C8809 and C9433 for 24 hrs in the 
presence and absence of 0.2 U/mL IFNγ and IRF1 induction was detected by immunoblotting. 20 U/mL IFNγ 
treated cells served as positive controls. (g) BMDM were treated with different doses of C8809 and C9433 for 
6 hrs and probed with anti-LC3B mAb. A mix of chloroquine(10 μM) and rapamycin(500 nM) served as positive 
control (C). All immunoblots are representative of at least two independent experiments. (h) BMDM were 
treated with 15 ng/mL TNFα and 10 U/mL IFNγ for 24 hrs in the presence of different doses of C8809 and NO 
production was measured in triplicates. (i) BMDM were treated with 10 ng/ml TNFα in the presence of C8809 
for 24 hrs. mRNA expression of IFNβ , IP10 and IL10 were measured by q-PCR. Data is calculated as % of gene 
expression relative to 10 ng/mL TNFα treated cells. All q-PCR results were normalized to expression of 18S and 
are representative of at least two independent experiments.
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for cancer therapy based on their ability to target the malignant anabolic state22 by inhibiting cap-dependent pro-
tein translation and HSF1 activity. In addition, rocaglamides have been shown to bind prohibitins, and suppress 
MEK-ERK signaling and cell cycle progression in malignant cells46.
Notably, it was shown that rocaglamide and its derivatives represent highly potent and specific inhibitors of 
TNFα -R or PMA-induced NF-κ B activity in different mouse and human T cell lines47. A synthetic derivative of 
rocaglaol was able to reduce tissue inflammation and neuronal cell death in vivo by inhibiting NF-κ B and AP-1 
signaling, resulting in significant neuroprotection in animal models of neurodegeneration48. In addition, some 
rocaglamide derivatives have been suggested as a new source of NF-AT specific inhibitors for the treatment of 
certain inflammatory diseases49. Currently it is unknown whether biological properties of rocaglamide derivatives 
may be explained by a common mechanism, such as inhibition of cap-dependent translation or several pathways 
are being engaged simultaneously or selectively.
Here in we report a novel activity of rocaglates- a synergistic effect with low doses of IFNγ on activation of Irf1 
mRNA expression in primary (non-transformed) macrophages. IRF1 protein is a major transcription factor in 
the IFNγ -regulated network50, which is essential for host resistance to TB and other intracellular pathogens51–53. 
Its up-regulation may lead to global macrophage reprogramming beneficial for host resistance to intracellular 
pathogens.
Considering possible mechanisms of synergy between a rocaglate and IFNγ , we envision several scenarios 
based on rocaglate-mediated translational inhibition. First, the Irf1 gene is a direct transcriptional target of IFNγ , 
based on the gamma-activated site (GAS) site element in its promoter, an element that overlaps with a NF-κ B 
motif30. The overlap accounts for synergistic interactions of IFNγ and NF-κ B pathways in the control of Irf1 gene 
expression. The NF-κ B pathway can be activated by translation inhibition directly by changing stoichiometry of 
activating and inhibiting subunits54. This effect is much less potent as compared to NF-κ B activation induced via 
TNFα -R. However, subthreshold activation of NF-κ B by a rocaglate in combination with low dose of IFNγ may 
produce synergistic effect on Irf1 due to the overlapping GAS/NF-κ B elements in its promoter. Second, transla-
tion inhibitors were shown to induce activation of stress kinases, including JNK, that activate the AP-1 transcrip-
tion complex, which may synergize with STAT1 on the Irf1 promoter55,56.
Another, more selective, mechanism may be explained by the ability of rocaglates to specifically inhibit 
cap-dependent protein translation by binding to and inhibiting the RNA helicase eIF4A. Thus, they do not 
block protein translation in general, but induce a switch from cap-dependent to cap-independent translation. 
This switch plays a physiological role in cell adaptation to stress conditions, where cap-dependent transla-
tion is repressed because of eIF2α phosphorylation by stress kinases. For example, control of translation via 
protein-regulated upstream open reading frames (uORFs) that inhibit translation initiation of stress-responsive 
downstream ORFs has been demonstrated57. Blocking the cap-dependent uORF translation up-regulates 
translation of a set of stress-responsive proteins58. Also, many proteins involved in stress responses and sur-
vival are translated in cap-independent manner using internal ribosome entry sites (IRES)59. The blockade of 
cap-dependent translation may serve an especially important signaling role in macrophages that, as a rule, must 
adapt to and perform their functions in particularly stressful environments.
Interestingly IFNγ itself regulates protein translation via up-regulation and activation of PKR, subsequent 
eIF2α phosphorylation and translational repression60,61. Meanwhile, a pool of interferon-stimulated pro-
teins increases62. Perhaps, rocaglate-induced inhibition of cap-dependent translation potentiates this effect of 
IFNγ , which shifts translational activity towards cap-independent translation via uORF and IRES-dependent 
Figure 6. Chemical structures of rocaglates used in the study. 
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mechanisms leading to remodeling of the macrophage proteome more towards stress- and activation-induced 
pattern. Thus, inhibition of cap-dependent translation by IFNγ and rocaglates may mimic stress and induce stress 
response proteins to facilitate macrophage pre-adaptation to imminent stress and, thus, increase their resilience 
to subsequent challenges.
Importantly, not all proteins are equally sensitive to inhibition of eIF4A helicase activity. A recent study 
identified the hallmarks of eIF4A-dependent transcripts using transcriptome-scale ribosome footprinting. 
These include specific UTR sequences that can form complex RNA G-quadruplex structures63. Thus, the heli-
case dependence of protein translation is necessitated by the presence of mRNA tertiary structures in specific 
transcripts. This model suggests that compounds that quantitatively differ in eIF4A RNA helicase inhibition 
may differentially affect protein subsets. Notably, among the most eIF4A-dependent and rocaglate-sensitive 
Figure 7. Comaparative activity of known rocaglates and translational inhibitors. (a) BMDM were treated 
with 0.33 μM compounds in presence of 0.2 U/mL IFNγ for 24 hr. mRNA expression of Irf1 was measured by 
qPCR and normalized to expression of 18 S. Data is presented relative to expression in 0.2U IFNγ treated cells 
(set as 1) and represents results from two independent experiments. (b) BMDM were treated with silvestrol 
and RHT at concentrations shown for 24 hrs and % of PI positive cells were calculated. Data is represented as 
% of survival of two independent experiments performed in duplicates. (c) BMDM were treated with 15 ng/mL 
TNFα and 10 U/mL IFNγ for 24 hrs in the presence and absence of 1 μM compounds and production of NO 
(assayed as NO2−) was determined. All measurements for NO production were performed in triplicates.  
(d) BMDM were treated with 1 μM compounds for 6 hrs and autophagy was determined by increase of LC3B-II 
to LC3B-I ratio by immunoblotting. Blots represent data of two independent experiments. 293 T-FLuc cells were 
treated with different doses of (e) silvestrol, RHT, exo-RHT and ent-RHT and (f) cycloheximide and rapamycin. 
The luciferase activity was measured after 18 hrs. Data represents values from experiment performed in 
triplicates. (g) BMDM were treated with cycloheximide and rapamycin at concentrations shown for 24 hrs and 
% of PI positive cells were calculated. Data is represented as % of survival of two independent experiments 
performed in duplicates. (h) BMDM were treated with 0.33 μM compounds in presence of 0.2 U/mL IFNγ for 
24 hr. mRNA expression of Irf1, Irf5 and Ptgs2 was measured by qPCR and normalized to expression of 18 S. 
Data is presented relative to expression in 0.2U IFNγ treated cells (set as 1) and represents results from two 
independent experiments. (i) BMDM were treated with 0.33, 1 and 3.3 μM rapamycin in presence of 0.2 U/mL 
IFNγ for 24 hr. mRNA expression of Irf1, Irf5 and Ptgs2 was measured by qPCR and normalized to expression 
of 18S. Data is presented relative to expression in 0.2U IFNγ treated cells (set as 1) and represents results from 
two independent experiments.
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transcripts were a number of oncogenes, superenhancer-associated transcription factors, and epigenetic regula-
tors. Conceivably, some rocaglates may synergize with IFNγ in macrophages by blocking translation of a particu-
lar subset of proteins that oppose macrophage activation, such as growth factor-induced oncogenes for example. 
Therefore, use of rocaglate derivatives with varying inhibitory activities may serve to fine tune cell responses in 
a cell type-and activation-specific manner. The novel rocaglates identified in this study are overall weaker trans-
lation inhibitors as compared to RHT and silvestrol, the later being known as powerful inhibitors of translation 
which are cytotoxic to leukemic cells. Accordingly, the new rocaglates are less toxic in primary macrophages 
and their effect on macrophage gene expression may be more selective. There is also a possibility that a subset of 
rocaglates may target other RNA/DEAD Box helicases in macrophages in addition to eIF4A. Attempts to identify 
potential new targets and pathways of rocaglate compounds that may synergize with IFNγ in macrophage activa-
tion are underway in our laboratories.
Taken together our studies have revealed a novel property of a subset of rocaglates to synergize with IFNγ in 
macrophage activation, which may lead to the development of macrophage-directed therapies that target specific 
aspects of macrophage activation. The ultimate goal of these therapies would be to reduce inflammatory tissue 
damage in vivo by improving macrophage resilience and fine-tuning their effector functions for specific infections 
and inflammatory conditions.
Materials and Methods
Mice. C57BL/6 J mice were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA). All experi-
ments were performed with the full knowledge and approval of the Standing Committee on Animals at Boston 
University in accordance with relevant guidelines and regulations (IACUC protocol number AN15276).
Cell lines, BMDMs culture. Mouse macrophage cell line J774A.1 was cultured in DMEM/F12 containing 
10% fetal bovine serum supplemented with 1% glutamine, penicillin and streptomycin (100 U/mL and 100 μg/
mL respectively) and 10 mM Hepes buffer (complete medium). J7-21 cell line generated in our lab by stable trans-
duction of GFP-Ipr1 in J774A.1 cells. Isolation of mouse bone marrow and culture of BMDMs were carried out as 
previously described21. iBMM stably expressing EGFP-LC3(GFP-LC3) was a kind gift from Hardy Cornfield and 
grown in complete medium. 293TR-FLuc cells that stably express Renilla firefly luciferase was grown in complete 
medium and was a gift from Luke Whitesell of Whitehead Institute.
Growth of F. tularensis LVS and macrophage infection. F. tularensis live vaccine strain (LVS) were 
grown in Brain-Heart Infusion broth overnight, harvested and then diluted in media without antibiotics to get 
the desired MOI. BMDM were seeded in tissue culture plates. At time of infection cells were washed with media 
without antibiotics and infected at indicated MOI. The plates were then centrifuged at 500 × g for 15 minutes and 
incubated for 1 hr at 37 °C with 5% CO2. Cells were then washed with fresh media, and incubated for 45 min at 
37 °C with media containing gentamicin (50 μg/mL) to kill any extracellular bacteria. Cells were washed again and 
cultured in DMEM/F12/10% FBS medium without antibiotic at 37 °C in 5% CO2.
Optimization and validation of assay. The macrophage cell line J774 was transduced with lentiviral 
constructs for Dox- inducible GFP-Ipr1 expression and clones were selected that had negligible basal level of 
GFP- Ipr1 expression and high inducibility with IFNγ . Using these clones eliminated background and greatly 
improved the assay sensitivity and reproducibility, crucial factors for the high throughput analyses. One such 
clone, clone 21 (J7-21), was used in further studies21. First, we tested different concentrations of IFNγ (0.05–50 U/
mL) and time points (24, 48 hrs) after addition of Dox to determine optimal assay conditions. Celigo Cytometer 
was used to measure number of GFP-Ipr1 positive cells and GFP-Ipr1 fluorescence intensity per nucleus after 
counterstaining with nuclear stain DAPI. Fluorescence intensity was maximal after 48 hrs of IFNγ priming and 
24 hrs after addition of Dox (optimal dose of Dox has been determined as well). This and several similar optimi-
zation experiments were performed in 96-well plate format. J7-21 cells were plated in 96 well plates at 7,000 cells 
per well, primed with increasing concentrations of IFNγ ranging from 0.05 to − 25 U/mL for 48 hrs, Dox was 
added for the last 24 hrs and the GFP-Ipr1 fluorescent cells were counted using Celigo Cytometer. We observed 
increase in signal at 0.2 U/mL of IFNγ , while the maximal levels were achieved at 10 U/mL. The dose-response 
curve demonstrated the high sensitivity and linearity of the assay in the range of 0.2–10 U/mL of IFNγ . Given its 
wide dynamic range, the assay can, in principle was used to screen for activators of IFNγ priming using 0.2 U/mL 
of IFNγ . We developed a gating strategy to identify the hits. The fluorescence intensity of GFP-Ipr1 at 0.2 U/mL 
IFNγ was set as a threshold for our gating and we selected hits based on compounds that showed at least four fold 
increase in GFP-Ipr1 signal above the background.
Library screening. Screening was carried out at the high throughput screening facility at Boston University. 
The ICCB and the LOPAC library stocks were provided by the screening facility. J7-21 cells were seeded at 7000 
cells per well in 96 well plates the previous day and compounds were added in the presence of 0.2 U/mL IFNγ . 
Final compound concentrations in the initial screen were approximately 1 μM. After 24 hrs, 1 μg/mL dox was 
added and GFP-Ipr1 expression was measured 24 hrs later using celigo cytometer. The wells were scored based on 
fluorescent intensity of GFP-Ipr1. Interferon-gamma (Peprotech) used at a concentration of 10 U/mL served as a 
positive control. For all follow-up work, the BU-CMD compounds were resynthesized, validated as referenced in 
the text. The commercially available compounds from ICCB and LOPAC were purchased from Enzo life sciences.
Chemical Synthesis. Synthetic compounds were obtained from the chemical collection at the BU Center 
for Molecular Discovery (BU-CMD). Compounds including C5557, C8808, and C8809 were synthesized using 
the reported procedures64.
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Immunoblotting. To monitor the Ipr1 protein levels we have developed Ipr1 peptide-specific rabbit poly-
clonal antibodies, which recognized the Ipr1 protein of predicted length on Western blots in nuclear, but not cyto-
plasmic, extracts of IFNγ -treated J774A.1 cells( Supplementary Fig. S1). J7-21 cells and BMDM’s were subjected 
to treatments specified in the text. Nuclear extracts were prepared as mentioned previously21. Whole cell extracts 
were prepared by lysing the cells in RIPA buffer supplemented with protease inhibitor cocktail and phosphatase 
inhibitor I and II (Sigma). Equal amounts (30 μg) of protein from whole-cell extracts was separated by SDS-PAGE 
and transferred to PVDF membrane (Millipore). After blocking with 5% skim milk in TBS-T buffer [20 mM Tris–
HCl (pH 7.5), 150 mM NaCl, and 0.1% Tween20] for 2 hour, the membranes were incubated with the primary 
antibody overnight at 4 °C. Bands were detected with enhanced chemiluminescence (ECL) kit (Perkin Elmer). 
Stripping was performed using WB stripping solution (Thermo scientific). The loading control β -actin (Sigma, 
1:2000) was evaluated on the same membrane. The Ipr1-specific rabbit anti-serum was generated by Covance 
Research Products, Inc. (Denver, CO, USA). (1:500) and described previously21. The Ipr1 monoclonal antibodies 
were generated using Ipr1 peptides from Abmart. LC3B antibodies were obtained from Cell signaling(1:250). 
LC3 II/LC3 I ratio was calculated for each blot by densitometric analysis. IRF1 antibody was obtained from Cell 
Signalling (1:500). Fold induction of IRF1 was calculated relative to untreated (set as 1) by densitometric analysis 
after normalizing it to loading control β -actin.
RNA Isolation and quantitative PCR. Total RNA was isolated using the RNeasy Plus mini kit (Qiagen). 
cDNA synthesis was performed using the SuperScript II (Invitrogen). Real-time PCR was performed with the 
GoTaq qPCR Mastermix (Promega) using the CFX-90 real-time PCR System (Bio-Rad). Oligonucleotide primers 
were designed using Primer 3 software (Supplementary Table S2) and specificity was confirmed by melting curve 
analysis. Thermal cycling parameters involved 40 cycles under the following conditions: 95 °C for 2 mins, 95 °C 
for 15 s and 60 °C for 30 s. Each sample was set up in triplicate and normalized to RPS17 or 18 S expression by the 
DDCt method.
Immunofluorescence microscopy. Cells were fixed with 4% paraformaldehyde for 15 min at room tem-
perature, permeabilised with 0.25% Triton-X for 30 min and then blocked for 20 min with goat-serum (2.5%). 
Cells were incubated with primary antibodies [mouse monoclonal antibodies against Ipr1(1:2000), iNOS(1:200) 
and LC3B(1:250)] overnight at 4 °C in 2.5% goat serum, and incubated with Alexa Fluor 594-conjugated donkey 
anti-mouse IgG (excitation/emission maxima ~ 590/617 nm) or Alexa Fluor 488- conjugated donkey anti-mouse 
IgG (excitation/emission maxima ~ 490/525 nm) (1:1000, Invitrogen) secondary antibody for 2 hrs. F.t. LVS were 
detected with anti-mouse F.t. LVS antibodies (1:1000). BMDMs from C57BL/6 J mice were grown in coverslips 
and treated with compounds with indicated time and autophagy was detected using the cyto-ID Autophagy 
detection kit (Enzo lifesciences) using FITC channel. Images were taken immediately in Nikon-deconvolution 
microscope. To detect autophagy in immortalized GFP-LC3 + (ex/emi max ~488/510 nm), iBMM was grown as 
mentioned previously65 and samples were processed as mentioned above. Images were acquired using Leica SP5 
confocal microscope. All images were processed using Image J software.
Measurement of nitrite concentration. To measure nitrite (NO2−), 50 μL of macrophage culture supernatant 
was collected, mixed with an equal volume of Griess reagent (1% sulfanilamide/0.1% N-(1-naphthyl)- 
ethylenediamine dihydrochloride/2.5% H3PO4) and incubated for 10 min at room temperature. Nitrite concen-
tration was determined by measuring the absorbance at 540 nm.
Hoechst/PI Staining Method for cell cytotoxicity. For cell viability assays J7-21 cells or BMDM were 
plated in 96 well tissue culture plates (12000 cells/well) and subjected to necessary treatments. The supernatant 
was aspirated and to each well 100 μl PBS containing Hoechst (Invitrogen, 10 μM) and PI (Calbiochem, 2 μM) 
were added. The plates were kept at 37 °C for 15 min and read in an automated cell cytometer. The % of total and 
dead cells was calculated for each treatment.
Reporter assay for measuring translation inhibition. 293TR-Fluc cells were grown to confluence and 
maintained in complete medium. 10,000 cells were plated in a 96-well clear bottom plate in complete medium 
without phenol-red. Compounds were added at different dilutions and kept for 18 hrs. The next day the media 
was removed and 100 ul of Nanolight Firefly Luc Assay reagent was added to the wells and the luminescence was 
measured using a Tecan-plate reader after 2 mins. Cells treated with DMSO served as negative controls and with 
100 μg/mL cycloheximide served as positive controls. Percentage of translation inhibition for each compound was 
calculated in triplicates from two independent experiments.
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